Importantly, in the context of CHF, two studies have now demonstrated that GLP-1 analogues also exert beneficial actions on post-MI survival and cardiac structure/function in rodent models independent of acute infarct-limiting and metabolic effects [12, 23], suggesting that GLP-1 may directly protect against chronic cardiac remodelling. The gene discussed is GCG; the disease is myocardial infarction.